ALX1 / KNOW Bio, Vast Therapeutics - LARVOL DELTA

Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Vast Therapeutics

New P2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Inhaled ALX1 Safety, Tolerability, and Dose Dependent Pharmacokinetics in Phase 1 Study: A Novel Approach for Targeted Delivery of Nitric Oxide to the Lungs (ATS 2026) - No abstract available

Clinical • Late-breaking abstract • P1 data • PK/PD data

Nitric oxide-releasing prodrug eradicates Pseudomonas aeruginosa and reduces inflammation in a mucus-producing rat model for CF (NACFC 2025) - "The therapeutic potential of an inhaled NO-releasing prodrug was demonstrated in a pre-clinical mucus-producing CF rodent model of chronic infection and neutrophilic inflammation caused by P. aeruginosa. Given NO's activity against other pathogens including non-tuberculosis mycobacteria (NTM)4 and the ability to elude antimicrobial resistance,5 ALX1 represents an attractive strategy for treating respiratory infections broadly."

Preclinical • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CFTR • IL1B • IL6 • TNFA

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer (PRNewswire) - "Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis....Vast plans to initiate its Phase 1 clinical development program in Q2 2024 and one or more proof-of-concept studies in subjects with bronchiectasis in 2025."

New P1 trial • Non‐Cystic Fibrosis Bronchiectasis